4 completed, 1 recruiting, 1 withdrawn. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Recruiting 1, Withdrawn 1 |
Follow lifitegrast: new trials by email Literature Review of lifitegrast trials Research Report on lifitegrast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease Lifitegrast/perfluorohexyloctane (PFHO) - Dry Eye Disease | Phase 3 | Withdrawn | Bausch & Lomb Incorporated | 2025-12-01 | 2025-12-10 | |
| Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease Drug placebo - Dry Eye Disease (DED) | Phase 3 | Recruiting | Lunan Better Pharmaceutical Co., LTD. | 820 | 2024-03-28 | 2025-03-17 |
| A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3) Lifitegrast, Placebo - Dry Eye Disease | Phase 3 | Completed | Shire | 711 | 2014-11-06 | 2021-06-11 |
| A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye Lifitegrast, Placebo - Dry Eye Disease | Phase 3 | Completed | Shire | 720 | 2012-12-07 | 2021-06-23 |
| Safety Study of Lifitegrast to Treat Dry Eye Lifitegrast, Placebo - Dry Eye Disease | Phase 3 | Completed | Shire | 332 | 2012-10-16 | 2021-06-11 |
| Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1) Lifitegrast, Placebo - Keratoconjunctivitis Sicca, Dry Eye Disease | Phase 3 | Completed | Shire | 588 | 2011-08-29 | 2021-06-11 |
Dry Eye Syndromes (6) · Keratoconjunctivitis Sicca (1)
Shire (4) · Bausch & Lomb Incorporated (1) · Lunan Better Pharmaceutical Co., LTD. (1)
United States (4) · China (1)
PMID 24289915, PMID 26365210, PMID 27055211, PMID 28079022, PMID 34617974